METAP2 INHIBITORS AND METHODS OF TREATING OBESITY

    公开(公告)号:US20180271856A1

    公开(公告)日:2018-09-27

    申请号:US15993059

    申请日:2018-05-30

    申请人: SynDevRx, Inc.

    摘要: The present invention relates to modified or polymer conjugated MetAP2 inhibitors. The present invention also relates to methods of preventing, inducing, causing or increasing weight loss, treating obesity and/or treating metabolic syndrome utilizing the modified or polymer conjugated MetAP2 inhibitors. The present invention also relates to methods of improving insulin sensitivity and glycemic control, reducing insulin levels and/or improving leptin sensitivity utilizing the modified or polymer conjugated MetAP2 inhibitors.

    METAP2 INHIBITORS AND METHODS OF TREATING OBESITY
    6.
    发明申请
    METAP2 INHIBITORS AND METHODS OF TREATING OBESITY 有权
    METAP2抑制剂和治疗肥胖症的方法

    公开(公告)号:US20170028014A1

    公开(公告)日:2017-02-02

    申请号:US15226267

    申请日:2016-08-02

    申请人: SynDevRx, Inc.

    IPC分类号: A61K38/06 A61K31/336

    摘要: The present invention relates to modified or polymer conjugated MetAP2 inhibitors. The present invention also relates to methods of preventing, inducing, causing or increasing weight loss, treating obesity and/or treating metabolic syndrome utilizing the modified or polymer conjugated MetAP2 inhibitors. The present invention also relates to methods of improving insulin sensitivity and glycemic control, reducing insulin levels and/or improving leptin sensitivity utilizing the modified or polymer conjugated MetAP2 inhibitors.

    摘要翻译: 本发明涉及修饰或聚合物缀合的MetAP2抑制剂。 本发明还涉及使用改性或聚合物缀合的MetAP2抑制剂来预防,诱导,引起或增加体重减轻,治疗肥胖症和/或治疗代谢综合征的方法。 本发明还涉及利用改性或聚合物缀合的MetAP2抑制剂来改善胰岛素敏感性和血糖控制,降低胰岛素水平和/或改善瘦蛋白敏感性的方法。

    Biomarkers of METAP2 inhibitors and applications thereof

    公开(公告)号:US11612577B2

    公开(公告)日:2023-03-28

    申请号:US16666249

    申请日:2019-10-28

    申请人: SynDevRx, Inc.

    摘要: The present disclosure relates to small molecule or polymer conjugated MetAP2 inhibitors. The present disclosure also relates to methods of treating, or ameliorating at least one symptom of metabolic dysfunction associated with a treatment in a subject having a disease, such as cancer. The present disclosure also relates to methods of treating, or ameliorating at least one symptom of cancer comprising administering a combination of a polymer conjugated MetAP2 inhibitors and at least one second agent wherein the second agent may induce metabolic dysfunction.